Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant bacterial infections, primarily in the lungs and wounds, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.